Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults
- PMID: 18312313
- DOI: 10.1111/j.1532-5415.2007.01637.x
Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults
Abstract
Objectives: To assess the association between total insulinlike growth factor (IGF)-1, IGF binding protein-1 (IGFBP-1), and IGFBP-3 levels and functioning and mortality in older adults.
Design: Cohort study.
Setting/participants: One thousand one hundred twenty-two individuals aged 65 and older without prior cardiovascular disease events participating in the Cardiovascular Health Study.
Measurements: Baseline fasting plasma levels of IGF-1, IGFBP-1, and IGFBP-3 (defined as tertiles, T1-T3) were examined in relationship to handgrip strength, time to walk 15 feet, development of new difficulties with activities of daily living (ADLs), and mortality.
Results: Higher IGFBP-1 predicted worse handgrip strength (P-trend(T1-T3)<.01) and slower walking speed (P-trend(T1-T3)=.03), lower IGF-1 had a borderline significant association with worse handgrip strength (P-trend(T1-T3)=.06), and better grip strength was observed in the middle IGFBP-3 tertile than in the low or high tertiles (P=.03). Adjusted for age, sex, and race, high IGFBP-1 predicted greater mortality (P-trend(T1-T3)<.001, hazard ratio (HR)(T3vsT1)=1.48, 95% confidence interval (CI)=1.15-1.90); this association was borderline significant after additional confounder adjustment (P-trend(T1-T3)=.05, HR(T3vsT1)=1.35, 95% CI=0.98-1.87). High IGFBP-1 was associated with greater risk of incident ADL difficulties after adjustment for age, sex, race, and other confounders (P-trend(T1-T3)=.04, HR(T3vsT1)=1.40, CI=1.01-1.94). Neither IGF-1 nor IGFBP-3 level predicted mortality or incident ADL difficulties.
Conclusion: In adults aged 65 and older, high IGFBP-1 levels were associated with greater risk of mortality and poorer functional ability, whereas IGF-1 and IGFBP-3 had little association with these outcomes.
Publication types
MeSH terms
Substances
Grants and funding
- 1R01HL083760-01/HL/NHLBI NIH HHS/United States
- N01 HC-15103/HC/NHLBI NIH HHS/United States
- N01 HC-55222/HC/NHLBI NIH HHS/United States
- N01-HC-35129/HC/NHLBI NIH HHS/United States
- N01-HC-45133/HC/NHLBI NIH HHS/United States
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-85084/HC/NHLBI NIH HHS/United States
- N01-HC-85085/HC/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
